Here are 1-3 brief analogies to describe Moderna (MRNA):

• It's like Pfizer or Merck, but focused entirely on developing its wide range of vaccines and therapeutics using groundbreaking messenger RNA (mRNA) technology.

• Consider it a biotech powerhouse, similar to Johnson & Johnson in its ambition to develop diverse medical solutions, but with its entire pipeline built upon the foundational messenger RNA (mRNA) platform.

• mRNA COVID-19 Vaccine (Spikevax): An authorized vaccine utilizing mRNA technology to protect against the SARS-CoV-2 virus.
• mRNA Prophylactic Vaccines: A pipeline of investigational vaccines designed to prevent various infectious diseases.
• mRNA Therapeutics: Developing a range of mRNA-based medicines for treating conditions such as cancer, rare diseases, cardiovascular, and autoimmune diseases.

Based on the provided company description, Moderna (MRNA) engages in strategic alliances and collaboration and license agreements with various entities. While these relationships are primarily for development and licensing, these partners often represent significant revenue streams and can be considered major customers for specific programs, technologies, or licensed products. Moderna, as a biotechnology company, primarily sells its products and intellectual property to other companies, governments, and healthcare systems, rather than directly to individuals.

The major public company customers identified through these strategic alliances and collaborations are:

• AstraZeneca PLC (Symbol: AZN)
• Merck & Co., Inc. (Symbol: MRK)
• Vertex Pharmaceuticals Incorporated (Symbol: VRTX)

• Lonza Group AG (LONN.SW)
• Catalent, Inc. (CTLT)
• Laboratorios Farmacéuticos Rovi, S.A. (ROVI.MC)

Stéphane Bancel – Chief Executive Officer

Stéphane Bancel has served as the Chief Executive Officer of Moderna since 2011, and is also a co-founder of the company. Prior to his tenure at Moderna, he was the CEO of the French diagnostics company BioMérieux from 2007 to 2011, where he was recognized for improving the company's financial margins. He also held various leadership roles at Eli Lilly and Company between 2000 and 2006, including managing director for Belgium and executive director of global manufacturing strategy and supply chain. Bancel is a partner at Flagship Pioneering and has served on the boards of companies such as Qiagen and Indigo Agriculture. He holds an MBA from Harvard Business School and master's degrees in engineering from CentraleSupélec and the University of Minnesota.

Jamey Mock – Chief Financial Officer

Jamey Mock was appointed Chief Financial Officer of Moderna in August 2022. Before joining Moderna, he served as the Senior Vice President and Chief Financial Officer of PerkinElmer, a life sciences and scientific instrument firm, from 2018. During his time at PerkinElmer, he oversaw the acquisition of BioLegend in 2021. Prior to PerkinElmer, Mock spent nearly two decades at General Electric (GE) in various finance and leadership positions. His career is characterized by consistent roles, having worked for only three companies.

Stephen Hoge, M.D. – President

Stephen Hoge has been Moderna's President and Head of Research since 2015. In this role, he leads the company's research and development initiatives, encompassing basic science, clinical development, regulatory affairs, and therapeutic areas. He joined Moderna in 2012 as Senior Vice President of Corporate Development. Before his time at Moderna, Dr. Hoge was a partner at McKinsey & Company and previously worked as an emergency room doctor in New York City.

Shannon Thyme Klinger – Chief Legal Officer and Corporate Secretary

Shannon Thyme Klinger is Moderna's Chief Legal Officer and Corporate Secretary, responsible for the company's legal strategies, governance, and corporate compliance. She also holds the position of President of the Moderna Charitable Foundation. Before joining Moderna in 2021, Klinger spent over ten years at Novartis in senior leadership roles, including Chief Legal Officer, Chief Ethics, Risk & Compliance Officer, Global Head of Litigation, and General Counsel.

Jerh Collins, Ph.D. – Chief Technical Operations and Quality Officer

Jerh Collins oversees Moderna's vaccine manufacturing, including quality, technical development, and supply across preclinical, clinical, and commercial programs. He joined Moderna in 2017. With over 30 years of leadership experience in the pharmaceutical industry, his background includes significant roles at companies such as Novartis and Merck.

1. Declining COVID-19 Vaccine Revenue and Dependence: Moderna faces a significant challenge with the rapid decline in demand for its COVID-19 vaccine, Spikevax, which was its primary revenue source. The company is transitioning from being a pandemic-driven powerhouse to a diversified biotech, and this shift is accompanied by a substantial drop in revenue and a "painful, but necessary, financial reset." Moderna's financial health is still heavily reliant on COVID-19 vaccine sales, with projections showing a continued decrease in revenue in the coming years.
2. Pipeline Execution and Intense Competition: To offset the decreasing COVID-19 vaccine revenue, Moderna's future prospects are largely dependent on the successful development and commercialization of new products from its pipeline. The company faces intense competition in key growth areas, such as the respiratory syncytial virus (RSV) vaccine market, where it competes with established players like Pfizer and GSK. There is also significant competition in emerging areas like oncology. The risk of pipeline failures, as demonstrated by the discontinuation of its Cytomegalovirus (CMV) program, is a continuous threat to its diversification strategy.
3. Intellectual Property Disputes: Moderna is involved in multiple patent infringement lawsuits, both as a plaintiff and a defendant, concerning its foundational mRNA technology and COVID-19 vaccines. These ongoing legal battles, such as BioNTech's lawsuit against Moderna for alleged patent infringement related to Moderna's next-generation COVID-19 shot, and Moderna's own suit against Pfizer and BioNTech, could result in significant royalty payments, substantial legal costs, or impact the company's ability to fully commercialize its mRNA platform.

The following are clear emerging threats for Moderna (MRNA):

• The sharp and ongoing decline in global demand for COVID-19 vaccines, which represented Moderna's primary revenue source during the pandemic, directly impacting its financial outlook.
• The successful market entry and significant penetration of non-mRNA vaccines for other major infectious diseases, such as Respiratory Syncytial Virus (RSV) by competitors using different technological platforms, potentially limiting the future market for Moderna's own mRNA-based vaccines in these key pipeline areas.

Moderna (MRNA) operates in several key therapeutic areas with significant addressable markets, primarily leveraging its messenger RNA (mRNA) platform. The addressable market sizes for their main products and services, primarily vaccines and therapeutics in development, are as follows:

• Overall mRNA Therapeutics Market (Global):
  • The global mRNA therapeutics market was valued at approximately USD 11.75 billion in 2023 and is projected to reach USD 31.30 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 17.05% from 2024 to 2030.
  • Another estimate places the global mRNA therapeutics market size at USD 17.25 billion in 2025, with a projection to surpass USD 83.49 billion by 2035, exhibiting a CAGR of 17.08% from 2025 to 2035.
  • In 2024, the market size was approximately USD 10.66 billion, anticipated to grow to around USD 45.04 billion by 2034 with a CAGR of 15.5% from 2025 to 2034.
  • North America is a dominant region within this market, accounting for 40.37% of the revenue share in 2023 and 40.75% in 2025.
• Infectious Disease Vaccines (mRNA-based):
  • The global mRNA vaccine market was valued at USD 11.3 billion in 2022 and is estimated to reach USD 27.7 billion by 2032, with a CAGR of 9.6%.
  • The global infectious disease vaccines market size was USD 36.25 billion in 2024 and is predicted to increase to approximately USD 72.40 billion by 2034, expanding at a CAGR of 7.17% from 2025 to 2034. The mRNA vaccines segment within infectious disease vaccines is expected to grow at a notable CAGR between 2025 and 2034.
  • Moderna's COVID-19 vaccine, Spikevax, had forecast sales of USD 19.5 billion in 2022. However, sales for Spikevax were projected to fall to between USD 6 billion and USD 8 billion for 2023, and further decrease from USD 6.8 billion in 2023 to an estimated USD 3.2 billion in 2024.
• mRNA Cancer Vaccines and Therapeutics (Immuno-oncology):
  • The global mRNA cancer vaccines and therapeutics market size was approximately USD 71.22 billion in 2025 and is projected to grow to USD 82.67 billion in 2026, at a CAGR of 16.1%. It is expected to further reach USD 141.51 billion in 2030 with a CAGR of 14.4%.
  • Another report indicates the global mRNA cancer vaccine market was valued at USD 8.59 billion in 2025 and is anticipated to reach USD 15.69 billion by 2034, growing at a CAGR of 6.9% from 2025 to 2034.
  • The mRNA Cancer Vaccines and Therapeutics Market was valued at USD 6.246 billion in 2024 and is projected to reach USD 39.01 billion by 2035, at a CAGR of 18.12% from 2025 to 2035.
  • North America leads this market, valued at USD 2.0 billion in 2023 and projected to reach USD 9.06 billion by 2032.
• mRNA Therapeutics for Rare Diseases:
  • The global rare disease therapeutics market reached USD 154.64 billion in 2024 and is projected to reach USD 495.27 billion by 2033, expanding at a CAGR of 13.8% during 2025–2033.
  • RNA-based therapies within the rare disease therapeutics market were valued at USD 26 billion in 2024.
  • Rare genetic diseases are identified as attractive targets for mRNA therapeutics due to regulatory incentives and lower competition.

Expected Drivers of Future Revenue Growth for Moderna (MRNA) over the Next 2-3 Years

• International Expansion and Strategic Partnerships: Moderna anticipates significant revenue growth from international markets, aiming for a balanced geographic revenue mix between the U.S. and global regions by 2026. This expansion is supported by multi-year agreements in countries such as the UK, Canada, and Australia, with new strategic partnerships also being pursued in Latin America and Asia Pacific.
• Launch of New Infectious Disease Vaccines: The company plans to diversify its product portfolio with the introduction of new vaccines. This includes its seasonal flu vaccine and a combination flu/COVID-19 vaccine, which are under regulatory review in international markets. Additionally, a Phase 3 study for its norovirus vaccine is fully enrolled, with data expected in 2026, contributing to an expanding seasonal vaccine franchise.
• Advancement and Potential Approvals in Oncology and Rare Disease Pipelines: Moderna is investing in its oncology and rare disease therapeutic pipelines. Over the next three years, the company expects readouts from nine Phase 2 and Phase 3 oncology studies, including three Phase 3 programs for intismeran (mRNA-4157) for adjuvant melanoma and other cancers. A registrational study for the propionic acidemia candidate (mRNA-3927) has reached target enrollment, with data anticipated in 2026.
• Growth of Recently Launched Products: The continued expansion and strong uptake of mNEXSPIKE, Moderna's newer COVID-19 vaccine, in the U.S. and its planned launches in other countries are expected to be a significant contributor to revenue growth in the coming years.

Share Repurchases

• Moderna authorized a share repurchase program of up to $1 billion in August 2021, to be executed over a two-year period.
• In 2023, the company repurchased $1.153 billion in shares.
• As of August 1, 2025, Moderna had completed the repurchase of 9,530,147 shares for $1,337.93 million under the buyback announced on August 3, 2022.

Share Issuance

• Moderna's annual shares outstanding increased from 382 million in December 2023 to 386 million in December 2024, indicating new share issuances.
• Quarterly shares outstanding increased from 389 million in June 2025 to 391 million in September 2025, also reflecting new share issuances.

Inbound Investments

• In November 2025, Moderna secured a five-year term loan facility for up to $1.5 billion from Ares Management Credit Funds, with an initial draw of $600 million.
• The Coalition for Epidemic Preparedness Innovations (CEPI) is investing up to $54.3 million to support a pivotal Phase 3 clinical trial for Moderna's investigational mRNA-based H5 pandemic influenza vaccine candidate.
• Moderna finalized a long-term strategic partnership with the Government of Canada in April 2022 to establish an mRNA vaccine manufacturing facility in Quebec.

Outbound Investments

• Moderna plans to reinvest revenues generated from its seasonal vaccine franchise into its experimental oncology and rare disease therapeutics pipeline.
• The company is increasing its research and development investments in oncology.
• Moderna announced an investment of over $140 million to establish full end-to-end manufacturing for its mRNA medicines at its Norwood, Massachusetts campus.

Capital Expenditures

• Moderna's annual capital expenditures were $707 million in 2023, $1.051 billion in 2024, and $202 million in 2025.
• For 2026, capital expenditures are projected to be between $0.2 billion and $0.3 billion.
• In 2021, the company planned capital investments between $450 million and $550 million, focused on expanding manufacturing capacity for its COVID-19 vaccine, technology improvements, and global commercial operations.